Vivos Inc. Announces Launch of Groundbreaking RadioGel® Precision Radionuclide ... - Morningstar
Vivos Inc. initiates first human clinical trial for RadioGel® Precision Radionuclide Therapy™ in India, successfully treating five cancer patients. The trial aligns with the protocol for the planned Mayo Clinic study in the U.S., focusing on safety. Vivos continues discussions with the FDA to initiate trials at Mayo Clinic, aiming to expand indications for RadioGel® in the U.S. The study plans to expand to 30 patients, targeting various cancerous nodes, with results expected in H1 2025.
Highlighted Terms
Related News
Vivos Inc. initiates first human clinical trial for RadioGel® Precision Radionuclide Therapy™ in India, successfully treating five cancer patients. The trial aligns with the protocol for the planned Mayo Clinic study in the U.S., focusing on safety. Vivos continues discussions with the FDA to initiate trials at Mayo Clinic, aiming to expand indications for RadioGel® in the U.S. The study plans to expand to 30 patients, targeting various cancerous nodes, with results expected in H1 2025.